Meeting
2020 ASCO Virtual Scientific Program
Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.
Authors
Richard Lee O'Neal
University of Kentucky, Markey Cancer Center, Greenville, KY
Richard Lee O'Neal , Kandice Roberts , Zhonglin Hao , Susanne M. Arnold
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3053)
DOI
10.1200/JCO.2020.38.15_suppl.3053
Abstract #
3053
Poster Bd #
117
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2024 ASCO Annual Meeting
Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).
First Author: Khadjah Alshankati
Poster
2024 ASCO Genitourinary Cancers Symposium
Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.
First Author: Yu Fujiwara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Effect of PD-1/ PD-L1 and statin combination therapy on gastrointestinal toxicity related to immune checkpoint inhibitors and on survival.
First Author: Yinghong Wang